RenovaCare, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RCAR research report →
About the company
RenovaCare, Inc. , a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area.
- CEO
- Harmel Singh Rayat
- IPO
- 1996
- Employees
- 1
- HQ
- Scottsdale, AZ, US
Price Chart
- Market Cap
- $8.73K
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.52
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -94.75%
- ROIC
- -224.65%
- Revenue
- $0 · 0.00%
- Net Income
- $-4,465,306 · 53.23%
- EPS
- $-0.05 · 53.55%
- Op Income
- $-5,409,416
- FCF YoY
- 4.21%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -96.73
- Avg Volume
- 2.56K
Get TickerSpark's AI analysis on RCAR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 16, 16 | Kirkland Kenneth | other | 50,000 |
| Mar 16, 15 | Bold Thomas | other | 60,000 |
| Mar 16, 16 | Rosen Rhonda Beth | other | 20,000 |
| Mar 16, 16 | SIERCHIO JOSEPH | other | 50,000 |
| Feb 2, 16 | RAYAT HARMEL S | buy | 2,173,913 |
| Feb 2, 16 | RAYAT HARMEL S | other | 2,173,913 |
| Dec 31, 15 | RAYAT HARMEL S | other | 3,800,000 |
| Dec 31, 15 | RAYAT HARMEL S | other | 3,000,000 |
| Dec 31, 15 | RAYAT HARMEL S | other | 12,000 |
| Dec 31, 15 | RAYAT HARMEL S | other | 800,000 |
Our RCAR coverage
Recent articles, reports, and earnings notes.
No research on RCAR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RCAR report →Similar companies
Peers in the same neighborhood.